These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38488755)

  • 21. Canadian, European and United States new drug approval times now relatively similar.
    Rawson NSB
    Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving drug regulatory landscape in China: A clinical pharmacology perspective.
    Tang W; Huang Y; Zhou D; Huang Y; Chen Y; Ren S; Li Y; Wu S; Zhao X; Song X; Wang H; Jin Y; Yu H; Zhang L; Li Y; Boulton D; Shen K
    Clin Transl Sci; 2021 Jul; 14(4):1222-1230. PubMed ID: 33503308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective.
    Jiang Y; Liu P; Qiu Z; Zhou M; Cheng M; Yang T
    Eur J Med Chem; 2024 Sep; 275():116593. PubMed ID: 38889609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory review of novel therapeutics--comparison of three regulatory agencies.
    Downing NS; Aminawung JA; Shah ND; Braunstein JB; Krumholz HM; Ross JS
    N Engl J Med; 2012 Jun; 366(24):2284-93. PubMed ID: 22591257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
    da Costa Gonçalves F; Demirci E; Zwiers A
    Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel targeted drugs approved by the NMPA and FDA in 2019.
    Wang W; Sun Q
    Signal Transduct Target Ther; 2020 May; 5(1):65. PubMed ID: 32385226
    [No Abstract]   [Full Text] [Related]  

  • 28. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
    J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drug approvals for 2020: Synthesis and clinical applications.
    Yuan S; Luo YQ; Zuo JH; Liu H; Li F; Yu B
    Eur J Med Chem; 2021 Apr; 215():113284. PubMed ID: 33611190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
    Hirota S; Yamaguchi T
    Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Twenty-year History and Future Challenges in Transparency Enhancement of Review Process for Approval: Focus on Public Release of Review Reports regarding New Drugs and Medical Devices].
    Morimoto K; Kawasaki S; Yoshida Y
    Yakushigaku Zasshi; 2015; 50(1):64-77. PubMed ID: 26427100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European Union.
    Fukuda K; Narukawa M
    Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1331-1340. PubMed ID: 37395168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The year's new drugs and biologics 2019.
    Graul AI; Pina P; Tracy M; Sorbera L
    Drugs Today (Barc); 2020 Jan; 56(1):47-103. PubMed ID: 32055805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The drug lag issue: a 20-year review of China.
    Li X; Yang Y
    Invest New Drugs; 2021 Oct; 39(5):1389-1398. PubMed ID: 33928468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.